Comparison
Fluridil vs Finasteride
Systemic suppression vs. pure topical AR downregulation — the battle for side-effect-free retention.
Fluridil
Topical Androgen Receptor Suppressor
Hairt½ ~6 hours (intact molecule, systemic); rapidly hydrolyzed in aqueous media
Finasteride
5α-Reductase Inhibitor (Type II/III)
Hairt½ 5–6 hours (plasma); pharmacodynamic effect ~24–48 hours
Effectiveness Profile
Fluridil
Finasteride
At a Glance
| Fluridil | Finasteride | |
|---|---|---|
| Type | Hair | Hair |
| Legal status | Research | Rx-Only |
| Half-life | ~6 hours (intact molecule, systemic); rapidly hydrolyzed in aqueous media | 5–6 hours (plasma); pharmacodynamic effect ~24–48 hours |
| Preferred route | Topical (scalp) | Oral |
| Dose frequency | once-daily | once-daily |
| Beginner dose | 1–2 ml | 0.25–1 mg |
| Intermediate dose | 2–2 ml | 1–1.25 mg |
| Advanced dose | 2–2 ml | 1–1.25 mg |
| Cycle length | 12–52 wks | 52–520 wks |
| Bioavailability | 0% | 72% |
| Time to peak | — | 1.5h |
| Active duration | 24h | 48h |
| Storage | Room temperature, sealed; keep anhydrous (water contact destroys the active) | Room temperature, 20–25°C, dry |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | No |
Verdict
Fluridil wins for:
- Zero systemic absorption: no measurable serum levels, HPTA impact, or sexual side effects.
- Cleanest side-effect profile thanks to rapid hydrolysis on contact with blood.
- Stacking compatibility: adds local AR suppression to any hair stack without compounding risk.
- Suitability for those who refuse (or can't tolerate) oral 5-AR inhibitors.
Finasteride wins for:
- Proven, potent DHT suppression and long-term hair retention/regrowth.
- Best-in-class clinical result for halting androgenetic alopecia progression.
- Simplicity: one oral or topical medication covers the majority of cases.
- Regrowth potential superior to pure topicals, especially in early/active loss.
Pick A or B?
Pick Fluridil if:
- The protocol requires zero systemic antiandrogenic activity (athletes, proven PFS risk, libido-sensitive users).
- The stack already includes oral or topical 5-AR inhibitors, and added local control is desired.
- Trials with finasteride/pyrilutamide/RU58841 caused intolerable sides or are hard-contraindicated.
- The scenario involves on-cycle AAS use where systemic DHT suppression is insufficient or undesirable.
- Research is focused on adding mild retention/thickening rather than reversing advanced loss.
Pick Finasteride if:
- The goal is maximal DHT suppression and clinical-grade hair retention/regrowth.
- The scenario involves early intervention or reversal attempts (Norwood 2–3).
- Simplicity, cost, and wide availability are priorities (oral generics).
- Willingness to accept manageable systemic risk (transient or dose-curbable)
- The cycle involves only testosterone (excluding compounds where finasteride backfires, e.g., nandrolone).
This comparison is presented for informational and educational purposes only. The compounds described may be research chemicals, prescription-only, or regulated substances in your jurisdiction. Consult a qualified medical professional before using any compound. This is not medical advice.